Paul Joseph Hampel

Paul Joseph Hampel

Auto-generated profile, based on publicly available information

Paul Joseph Hampel

Division of Hematology, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
PHPaul J. Hampel
Paul J. Hampel
SPSameer A. Parikh
Sameer A. Parikh
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as Bruton tyrosine kinase inhibitors and venetoclax) and next-generation anti-CD20 monoclonal antibodies (such as obinutuzumab). These agents lead to improved outcomes in patients with CLL, even among those with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes. Selecting the right treatment for the right patient requires consideration of disease characteristics and prior treatment sequence, as well as patient preferences and comorbidities. The CLL-International Prognostic Index (CLL-IPI) remains the best-validated tool in predicting the time to first therapy among previously untreated patients, which guides selection for early intervention efforts. This review summarizes our current approach to the management of CLL, right from the time of diagnosis through relapsed disease.

24 April 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PHPaul J. Hampel
Paul J. Hampel
WDWei Ding
Wei Ding
TCTimothy G. Call
Timothy G. Call
KRKari G. Rabe
Kari G. Rabe
SKSaad S. Kenderian
Saad S. Kenderian
SPSameer A. Parikh
Sameer A. Parikh
We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of 202 patients who received ibrutinib, 52 discontinued therapy (estimated 1- and 2-year risk of discontinuation 18% and 28%, respectively). The most common reasons for discontinuation were toxicity (56%) and progression of disease (32%, including Richter’s transformation in 15%). Rapid progression of disease within 4 weeks after discontinuation was observed in 9/36 (25%) patients with adequate records for review, mostly in those stopping ibrutinib for disease progression (n = 8) rather than toxicity (n = 1). This was evident by sudden worsening of disease-related symptoms (n = 9), exam/radiographic changes (n = 7), and laboratory changes (n = 8). An estimated one in every three patients discontinued ibrutinib by 2 years, with 25% developing rapid disease progression afterwards.

16 August 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
PHPaul J. Hampel
Paul J. Hampel
MLMelissa C. Larson
Melissa C. Larson
BKBrian Kabat
Brian Kabat
TCTimothy G. Call
Timothy G. Call
WDWei Ding
Wei Ding
SPSameer A. Parikh
Sameer A. Parikh

5 November 2021 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
EMEli Muchtar
Eli Muchtar
AKAmber B. Koehler
Amber B. Koehler
MJMichael J. Johnson
Michael J. Johnson
KRKari G. Rabe
Kari G. Rabe
WDWei Ding
Wei Ding
SPSameer A. Parikh
Sameer A. Parikh

17 July 2025 in Blood
Verified
Journal Article
Closed access
AKAdam S. Kittai
Adam S. Kittai
MMMonia Marchetti
Monia Marchetti
OAOthman Al-Sawaf
Othman Al-Sawaf
OBOhad Benjamini
Ohad Benjamini
ADAlexey V. Danilov
Alexey V. Danilov
PGPaolo Prospero Ghia
Paolo Prospero Ghia
Richter transformation (RT) is defined as an aggressive lymphoma emerging in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Despite novel therapeutics developed in CLL, RT is associated with poor outcomes. In light of recent progress regarding the diagnostic procedures and therapeutic concepts of RT, an international group of experts, under the coordination of the European Research Initiative on CLL, has developed consensus recommendations for clinical procedures and future research on this disease. Patients with RT typically present with a rapid clinical decline, worsening B-symptoms, elevated lactate dehydrogenase, and/or rapidly enlarging lymphadenopathy. Workup should include a positron emission tomography–computed tomography scan for patients with suspected RT. An excisional biopsy should be taken from an accessible lesion, preferably with the highest fluorodeoxyglucose avidity, and analyzed for the presence of aggressive lymphoma. The molecular relationship to the original CLL clone(s) should be defined. Because no effective standard treatment for RT exists, patients should be treated in a clinical trial. Response of both RT and CLL should be assessed at an early time point, and survival end points should be prioritized in trial design. We hope that these recommendations can help to harmonize clinical and translational research and improve outcomes for patients with RT.

20 September 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
PHPaul J. Hampel
Paul J. Hampel
TCTimothy G. Call
Timothy G. Call
KRKari G. Rabe
Kari G. Rabe
WDWei Ding
Wei Ding
EMEli Muchtar
Eli Muchtar
SPSameer A. Parikh
Sameer A. Parikh
Background: Approximately 25% of patients with chronic lymphocytic leukemia (CLL) experience a flare of disease following ibrutinib discontinuation. A critical question is whether this phenomenon may also occur when ibrutinib is temporarily held. This study aimed to determine the frequency and characteristics of disease flares in this setting and assess risk factors and clinical outcomes. Materials and Methods: We identified all patients with CLL seen at Mayo Clinic between October 2012 and March 2019 who received ibrutinib. Temporary interruptions in treatment and associated clinical findings were ascertained. Results: Among the 372 patients identified, 143 (38%) had at least one temporary interruption (median 1 hold, range 1–7 holds) in treatment. The median duration of interruption was 8 days (range 1–59 days) and the most common indication was periprocedural. Among the 143 patients with ≥1 hold, an associated disease flare was seen in 35 (25%) patients: mild (constitutional symptoms only) in 21 patients and severe (constitutional symptoms with exam/radiographic findings or laboratory changes) in 14 patients. Disease flare resolved with resuming ibrutinib in all patients. Predictive factors of disease flare included progressive disease at time of hold and ≥ 24 months of ibrutinib exposure. The occurrence of disease flare with an ibrutinib hold was associated with shorter event-free survival (hazard ratio 2.3; 95% confidence interval 1.3–4.1; p = .007) but not overall survival. Conclusion: Temporary interruptions in ibrutinib treatment of patients with CLL are common, and one quarter of patients who held ibrutinib in this study experienced a disease flare. Resolution with resuming ibrutinib underscores the importance of awareness of this phenomenon for optimal management. Implications for Practice: Ibrutinib is a very effective treatment for chronic lymphocytic leukemia (CLL) but needs to be taken continuously. Side effects, such as increased bleeding risk with procedures, require temporary interruptions in this continuous treatment. Rapid CLL progression following ibrutinib discontinuation has been increasingly recognized. This study demonstrates that similar flares in disease signs or symptoms may occur during ibrutinib holds as well. Importantly, management with restarting ibrutinib led to quick clinical improvement. Awareness of this phenomenon among clinicians is critical to avoid associated patient morbidity and premature cessation of effective treatment with ibrutinib if the flare is misidentified as true progression of disease.